Japan approves Solasia's Episil

Solasia Pharma K.K. (Tokyo:4597) said Japan's Ministry of Health, Labour and Welfare (MHLW) approved Episil (episil oral spray, SP-03) to manage and relieve pain due to oral lesions, including oral mucositis or stomatitis caused by chemotherapy or radiotherapy. The company said the approval is the first in Japan to treat pain associated with oral mucositis in cancer patients.

Solasia's partner Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) has Japanese rights to Episil. The therapy is a lipid-based liquid that transforms into a bioadhesive FluidCrystal film. It is marketed in the U.S. and Europe...